4-[[2-carbamoyl-5-chloro-3-[2-(phenoxymethyl)morpholin-4-yl]sulfonyl-1H-indol-7-yl]amino]-2-(sulfomethyl)piperidine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-[[2-carbamoyl-5-chloro-3-[2-(phenoxymethyl)morpholin-4-yl]sulfonyl-1H-indol-7-yl]amino]-2-(sulfomethyl)piperidine-1-carboxylic acid
• 化学式: C₂₇H₃₂ClN₅O₁₀S₂
• 分子量: 686.2
• InChiKey: WLDZCAHMEVIRRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  45
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  238
• 氢给体数：
  5
• 氢受体数：
  12

文献信息

• [EN] METHOD OF PREDICTING OR MONITORING RESPONSE TO IGF-1R AND IR INHIBITORS USING BIOMARKERS<br/>[FR] PROCÉDÉ DE PRÉDICTION OU DE SUIVI DE LA RÉPONSE À DES INHIBITEURS DES IGF-1R ET DES IR, FAISANT APPEL À DES BIOMARQUEURS
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2014002007A1

  公开（公告）日：2014-01-03

  The present invention relates to a method of monitoring response of a subject having cancer to treatment with a compound which is an Insulin Like Growth Factor-1 Receptor (IGF-1R) and Insulin Receptor (IR) inhibitor. The method of the present invention comprises comparing the expression level of at least one biomarker selected from the group consisting of Early Growth Response-1 (EGR-1), Dual Specificity Phosphatase-5 (DUSP-5) and FBJ murine osteosarcoma viral oncogene homolog (FOS) from a sample obtained from the subject having cancer before administering the compound and after administering the compound. Decrease in the expression level of at least one of said biomarker after administering the compound predicts the response of the subject to treatment with the said compound.